Mereo Biopharma Group Plc ADR (NASDAQ: MREO) is 97.40% higher on its value in year-to-date trading and has touched a low of $1.54 and a high of $5.02 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The MREO stock was last observed hovering at around $4.51 in the last trading session, with the day’s gains setting it 0.05%.
Currently trading at $4.56, the stock is 7.18% and 5.62% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.75 million and changing 1.11% at the moment leaves the stock 25.04% off its SMA200. MREO registered 154.75% gain for a year compared to 6-month gain of 72.08%. The firm has a 50-day simple moving average (SMA 50) of $4.3172 and a 200-day simple moving average (SMA200) of $3.646725.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 8.06% loss in the last 1 month and extending the period to 3 months gives it a 17.53%, and is 10.68% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.32% over the week and 4.50% over the month.
Distance from 52-week low is 196.10% and -9.16% from its 52-week high.
The EPS is expected to grow by 15.00% this year, but quarterly earnings will post 41.60% year-over-year.
87.0 institutions hold shares in Mereo Biopharma Group Plc ADR (MREO), with institutional investors hold 66.17% of the company’s shares. The shares outstanding are 153.76M, and float is at 141.76M with Short Float at 3.44%. Institutions hold 65.49% of the Float.
The top institutional shareholder in the company is RUBRIC CAPITAL MANAGEMENT LP with over 15.31 million shares valued at $55.11 million. The investor’s holdings represent 2.1859 of the MREO Shares outstanding. As of 2024-06-30, the second largest holder is ADAGE CAPITAL PARTNERS GP, L.L.C. with 11.79 million shares valued at $42.45 million to account for 1.6838 of the shares outstanding. The other top investors are ROCK SPRINGS CAPITAL MANAGEMENT LP which holds 9.28 million shares representing 1.3257 and valued at over $33.42 million, while MANGROVE PARTNERS holds 1.2499 of the shares totaling 8.75 million with a market value of $31.51 million.
Mereo Biopharma Group Plc ADR (MREO) Insider Activity
The most recent transaction is an insider sale by Scots-Knight Denise, the company’s Chief Executive Officer. SEC filings show that Scots-Knight Denise sold 60,046 shares of the company’s common stock on Sep 13 ’24 at a price of $4.22 per share for a total of $0.25 million. Following the sale, the insider now owns 0.81 million shares.
Mereo Biopharma Group Plc ADR disclosed in a document filed with the SEC on Sep 12 ’24 that Scots-Knight Denise (Chief Executive Officer) sold a total of 28,611 shares of the company’s common stock. The trade occurred on Sep 12 ’24 and was made at $4.47 per share for $0.13 million. Following the transaction, the insider now directly holds 0.87 million shares of the MREO stock.
Still, SEC filings show that on Sep 13 ’24, Lewicki John A. (Chief Scientific Officer) disposed off 10,937 shares at an average price of $4.22 for $46165.0. The insider now directly holds 78,630 shares of Mereo Biopharma Group Plc ADR (MREO).
